A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Abstract Text:

Kyle M Kampman,Charles Dackis,Kevin G Lynch,Helen Pettinati,Carlos Tirado,Peter Gariti,Thorne Sparkman,Michal Atzram,Charles P O'Brien,

BACKGROUND: This trial evaluated the efficacy of amantadine, propranolol and their combination in cocaine dependent patients with severe cocaine withdrawal symptoms. METHODS: Cocaine withdrawal symptom severity was measured by the cocaine selective severity assessment (CSSA). One hundred and ninety-nine patients with high scores on the CSSA participated in a 10-week double-blind trial. Patients were randomly assigned to receive amantadine (300 mg/day), propranolol (100mg/day), a combination of amantadine (300 mg/day) and propranolol (100mg/day) or matching placebo capsules. The primary outcome measure was cocaine abstinence. RESULTS: In the intent-to-treat sample, there were no significant differences between the four medication groups in treatment retention. The odds of cocaine abstinence showed a marginally significant increase over time in the propranolol group (p=0.06) but not in the other three groups. In highly medication-adherent patients, treatment retention was significantly better in the propranolol group compared to the placebo group (p=0.01) and the odds of cocaine abstinence increased significantly over time in the propranolol group but not in the other three groups. CONCLUSION: In the intent-to-treat sample, none of the three active treatments (propranolol, amantadine or their combination) was significantly more effective than placebo in promoting abstinence from cocaine among patients who entered treatment with more severe cocaine withdrawal symptoms. Among patients highly adherent to study medication, propranolol treatment was associated with better treatment retention and higher rates of cocaine abstinence compared to placebo.

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Publishing Authors By Initials

KM Kampman,C Dackis,KG Lynch,H Pettinati,C Tirado,P Gariti,T Sparkman,M Atzram,CP O'Brien,

For similar disorders of environmental origin: substance-related disorders: substance withdrawal syndrome research abstracts see: disorders of environmental origin: substance-related disorders: substance withdrawal syndrome research

PUBMED ID PMID:

MEDLINE DATE:

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Drug and alcohol dependence

VOLUME: 85

Page Numbers: 129-37

Journal Abbreviation:

ISSN: 0376-8716

DAY: 11

MONTH: 05

YEAR: 2006

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7513587

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Keywords Mesh Terms:

KEYWORDS: Substance Withdrawal Syndrome

MESH TERMS: rehabilitation

Chemical & Substance for Abstract: A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Information

Substance Name: Amantadine

Registry Number: 768-94-5

Grant and Affiliation Information for A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.

AFFILIATION: Department of Psychiatry, University of Pennsylvania School of Medicine, 3900 Chestnut Street, Philadelphia, PA 19104, USA. kampman_k@mail.trc.upenn.edu

Country: Ireland

AGENCY: United States NIDA

GRANT: P50 DA12756

ACRONYM: DA

MEDLINETA: Drug Alcohol Depend

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms Related Publications

• A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms.
• A new mechanism for generating TCR diversity: A TCR Jalpha-like gene that inserts partial nucleotide sequences in a D-gene manner.
• Activity dependent localization of synaptic NMDA receptors in spinal neurons.
• Age-related variation in red blood cell stable isotope ratios (delta13C and delta15N) from two Yupik villages in southwest Alaska: a pilot study.
• Application of three scattering models to characterization of solid tumors in mice.
• Changes in fat-free mass during significant weight loss: a systematic review.
• Characterizing the phospholipid profiles in mammalian tissues by MALDI FTMS.
• Chronic lymphocytic leukemia: current and emerging treatment approaches.
• Coexistence of aneurysmal subarachnoid haemorrhage and pituitary apoplexy: Case report and review of the literature.
• Deletion of the gene encoding the islet-specific glucose-6-phosphatase catalytic subunit-related protein autoantigen results in a mild metabolic phenotype.
• Deletion of the gene encoding the ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP)/glucose-6-phosphatase catalytic subunit-beta results in lowered plasma cholesterol and elevated glucagon.
• Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes.
• Expression of the spermatogenic cell-specific glyceraldehyde 3-phosphate dehydrogenase (GAPDS) in rat testis.
• HLA-B Bw4 alleles and HIV-1 transmission in heterosexual couples.
• Hemorrhage near fetal rat bone exposed to pulsed ultrasound.
• Hn08p audit of 115 consecutive parathyroidectomies in patients with renal hyperparathyroidism.
• Impact of local attenuation approximations when estimating correlation length from backscattered ultrasound echoes.
• Lesions of ultrasound-induced lung hemorrhage are not consistent with thermal injury.
• Mild cognitive impairment should be considered for DSM-V.
• Molecular cytotoxic mechanisms of catecholic polychlorinated biphenyl metabolites in isolated rat hepatocytes.
• Multiple glycolytic enzymes are tightly bound to the fibrous sheath of mouse spermatozoa.
• Occupational health problems of bridge and tunnel officers.
• Psychological aspects of premenstrual syndrome.
• Radiation exposure of aircrews.
• The interaction and cellular localization of HSP27 and ERbeta are modulated by 17beta-estradiol and HSP27 phosphorylation.
• The transformation of spinal curvature into spinal deformity: pathological processes and implications for treatment.
• Ultrasound-biophysics mechanisms.
• Vascular lesions and s-thrombomodulin concentrations from auricular arteries of rabbits infused with microbubble contrast agent and exposed to pulsed ultrasound.
• alpha-Tocopherol, but not gamma-tocopherol inhibits 7 beta-hydroxycholesterol-induced apoptosis in human U937 cells.
• gammadelta T lymphocytes-selectable cells within the innate system?